FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912967573> ?p ?o ?g. }

• W2912967573 endingPage "65" @default.
• W2912967573 startingPage "57" @default.
• W2912967573 abstract "Focal adhesion kinase (FAK) inhibitors have demonstrated anti-tumor activity preclinically and are currently being evaluated in humans. A first-in-human study evaluating the novel FAK inhibitor BI 853520 in a predominantly Caucasian population with advanced or metastatic non-hematologic malignancies demonstrated acceptable tolerability and favorable pharmacokinetics.This study was undertaken to investigate the safety, tolerability, and maximum tolerated dose (MTD) of BI 853520 in Japanese and Taiwanese patients with advanced solid tumors.In this open-label, phase I, dose-finding study, BI 853520 was administered once daily (QD) in a continuous daily dosing regimen with 28-day cycles and escalating doses to sequential cohorts of patients. Twenty-one patients (62% male; median age 65 years) were treated at two sites in Japan and Taiwan.The median duration of treatment was 1.2 months (range 0.2-7.7). As no dose-limiting toxicities were observed during cycle 1 in the 50, 100, or 200 mg cohorts, the MTD of BI 853520 was determined to be 200 mg QD. Drug-related adverse events were reported in 19 patients (90%), and all except one were of grade 1 or 2. Pharmacokinetic parameters were supportive of a once-daily dosing schedule. A confirmed objective response rate of 5% and disease control rate of 29% were achieved; median duration of disease control was 3.7 months.This trial demonstrated a manageable and acceptable safety profile, favorable pharmacokinetics, and potential anti-tumor activity of BI 853520 in pretreated Japanese and Taiwanese patients with advanced or metastatic solid tumors.NCT01905111." @default.
• W2912967573 created "2019-02-21" @default.
• W2912967573 creator A5001115937 @default.
• W2912967573 creator A5015799240 @default.
• W2912967573 creator A5020674154 @default.
• W2912967573 creator A5029171331 @default.
• W2912967573 creator A5031531907 @default.
• W2912967573 creator A5041769101 @default.
• W2912967573 creator A5052962058 @default.
• W2912967573 creator A5064272098 @default.
• W2912967573 creator A5080582585 @default.
• W2912967573 date "2019-02-01" @default.
• W2912967573 modified "2023-10-16" @default.
• W2912967573 title "Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors" @default.
• W2912967573 cites W1516077090 @default.
• W2912967573 cites W1524238275 @default.
• W2912967573 cites W1902804987 @default.
• W2912967573 cites W1964376417 @default.
• W2912967573 cites W1974215052 @default.
• W2912967573 cites W1985961293 @default.
• W2912967573 cites W2002736769 @default.
• W2912967573 cites W2006145157 @default.
• W2912967573 cites W2012347139 @default.
• W2912967573 cites W2019607817 @default.
• W2912967573 cites W2027218071 @default.
• W2912967573 cites W2036446081 @default.
• W2912967573 cites W2044423100 @default.
• W2912967573 cites W2055457865 @default.
• W2912967573 cites W2065088072 @default.
• W2912967573 cites W2068652698 @default.
• W2912967573 cites W2071368342 @default.
• W2912967573 cites W2098733531 @default.
• W2912967573 cites W2100757571 @default.
• W2912967573 cites W2107200488 @default.
• W2912967573 cites W2129041527 @default.
• W2912967573 cites W2134123153 @default.
• W2912967573 cites W2135604793 @default.
• W2912967573 cites W2147010494 @default.
• W2912967573 cites W2150236264 @default.
• W2912967573 cites W2155883999 @default.
• W2912967573 cites W2167452086 @default.
• W2912967573 cites W2314423784 @default.
• W2912967573 cites W2414519095 @default.
• W2912967573 cites W2469223980 @default.
• W2912967573 cites W2528438395 @default.
• W2912967573 cites W2789525187 @default.
• W2912967573 cites W2891572542 @default.
• W2912967573 cites W2913025776 @default.
• W2912967573 cites W2914232272 @default.
• W2912967573 doi "https://doi.org/10.1007/s11523-019-00620-0" @default.
• W2912967573 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6407737" @default.
• W2912967573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30725402" @default.
• W2912967573 hasPublicationYear "2019" @default.
• W2912967573 type Work @default.
• W2912967573 sameAs 2912967573 @default.
• W2912967573 citedByCount "19" @default.
• W2912967573 countsByYear W29129675732019 @default.
• W2912967573 countsByYear W29129675732020 @default.
• W2912967573 countsByYear W29129675732021 @default.
• W2912967573 countsByYear W29129675732022 @default.
• W2912967573 countsByYear W29129675732023 @default.
• W2912967573 crossrefType "journal-article" @default.
• W2912967573 hasAuthorship W2912967573A5001115937 @default.
• W2912967573 hasAuthorship W2912967573A5015799240 @default.
• W2912967573 hasAuthorship W2912967573A5020674154 @default.
• W2912967573 hasAuthorship W2912967573A5029171331 @default.
• W2912967573 hasAuthorship W2912967573A5031531907 @default.
• W2912967573 hasAuthorship W2912967573A5041769101 @default.
• W2912967573 hasAuthorship W2912967573A5052962058 @default.
• W2912967573 hasAuthorship W2912967573A5064272098 @default.
• W2912967573 hasAuthorship W2912967573A5080582585 @default.
• W2912967573 hasBestOaLocation W29129675731 @default.
• W2912967573 hasConcept C112705442 @default.
• W2912967573 hasConcept C126322002 @default.
• W2912967573 hasConcept C143998085 @default.
• W2912967573 hasConcept C197934379 @default.
• W2912967573 hasConcept C2777288759 @default.
• W2912967573 hasConcept C2778375690 @default.
• W2912967573 hasConcept C2779984678 @default.
• W2912967573 hasConcept C2781413609 @default.
• W2912967573 hasConcept C2908647359 @default.
• W2912967573 hasConcept C31760486 @default.
• W2912967573 hasConcept C535046627 @default.
• W2912967573 hasConcept C71924100 @default.
• W2912967573 hasConcept C90924648 @default.
• W2912967573 hasConcept C98274493 @default.
• W2912967573 hasConcept C99454951 @default.
• W2912967573 hasConceptScore W2912967573C112705442 @default.
• W2912967573 hasConceptScore W2912967573C126322002 @default.
• W2912967573 hasConceptScore W2912967573C143998085 @default.
• W2912967573 hasConceptScore W2912967573C197934379 @default.
• W2912967573 hasConceptScore W2912967573C2777288759 @default.
• W2912967573 hasConceptScore W2912967573C2778375690 @default.
• W2912967573 hasConceptScore W2912967573C2779984678 @default.
• W2912967573 hasConceptScore W2912967573C2781413609 @default.
• W2912967573 hasConceptScore W2912967573C2908647359 @default.
• W2912967573 hasConceptScore W2912967573C31760486 @default.
• W2912967573 hasConceptScore W2912967573C535046627 @default.

• next